Infimab Injection contains Infliximab 100 mg, a chimeric monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine involved in various autoimmune diseases. Infimab is indicated for the treatment of moderate to severe rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, and plaque psoriasis in patients who have had an inadequate response to conventional therapies. By binding specifically to TNF-α, Infimab inhibits its interaction with TNF receptors, thereby reducing inflammation and altering the immune response. The medication is administered via intravenous infusion under medical supervision, with dosing regimens tailored to the specific condition and patient response. Prior to initiation, screening for latent tuberculosis and other infections is essential due to the increased risk of serious infections associated with TNF inhibitors. Common adverse effects include infusion-related reactions, infections, headache, and gastrointestinal symptoms. Caution is advised in patients with a history of demyelinating disorders, congestive heart failure, or malignancies. Regular monitoring during therapy is recommended to assess efficacy and detect potential adverse events. Infimab should be used in accordance with established guidelines and under the supervision of a healthcare professional experienced in the management of autoimmune diseases.